Iconovo guides regarding value of generic Seebri® and Ultibro® for ICOcap® formulations
Iconovo announced July 8th that a regional licensing agreement had been signed with BNC Korea regarding the development of two inhalation capsule formulations for generic Ultibro® and Seebri® for ICOcap®. The agreement gives BNC Korea exclusive rights in a territory consisting of Korea, Japan, China, Taiwan, Russia, the CIS Countries and the Southeast Asian Countries (including Turkey). The deal has a milestones value of EUR 550.000 whereof EUR 150.000 is to be paid as an access fee. Iconovo estimates that most of the value will be in future royalty payments and not milestones payments.
Iconovo signs regional licensing agreement for ICOcap® formulations with BNC Korea
Iconovo announce that the company has signed a know-how license agreement granting BNC Korea Co Ltd the exclusive rights to use the know-how to manufacture the formulations and to market, sell and distribute the formulations together with ICOcap® in the territory. BNC Koreas has exclusive rights in a territory consisting of Korea, Japan, China, Taiwan, Russia, the CIS Countries and the Southeast Asian Countries (including Turkey). The license agreement covers two generic formulations, a generic Ultibro® Breezhaler® (indacaterol, glycopyrronium) product and a generic Seebri® Breezhaler® (glycopyrronium) product. The deal has a value of EUR 550,000 whereof EUR 150,000 is to be paid as an access fee. Royalties from future sales will be a mid-single digit percentage of sales depending on market.
Stevanato to invest in ICOcap® manufacturing
Stevanato announced in their industrial plan for 2020 – 2023 that they intend to invest almost Euro 400 million in manufacturing and R&D programs…
Iconovo release briefing document for ICOpre® development
Today, Iconovo released a briefing document on its homepage covering the market opportunity, patent situation, ICOpre® product features and partnering…
Positive decision about a Chinese ICOres® patent
The Chinese Patent Agency has announced the intention to grant a patent regarding Iconovo’s inhalation device, ICOres. Iconovo has previously granted…
Capsule inhaler ICOcap™ from Iconovo CE-marked for clinical trials
Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials. ICOcap™ is now available for customers…
Development of Iconovo AB’s generic Symbicort project transferred to the global partner Amneal
Iconovo AB today announced that the ICOres™ budesonide/formoterol project (generic Symbicort®) will be transferred to the global partner Amneal Ireland Limited from CBC Corporation (India) Private Limited. Amneal Ireland Limited will take over all existing obligations of CBC under the current agreement. The project will continue according to plan.
ICONOVO AB CARRIES OUT A DIRECTED SHARE ISSUE AND RAISES SEK 60 MILLION BEFORE ISSUE COSTS
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND,…
Iconovo has been granted ICOres patent in Japan
The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several granted ICOres patents in Sweden…
ICONOVO AND CRYSTECPHARMA TO COLLABORATE IN DEVELOPMENT OF INNOVATIVE INHALER PRODUCTS
Iconovo today announced that it signed a Letter of Understanding with CrystecPharma to collaborate in the development of innovative dry powder inhaler…